Profiel
James Joseph Mauzey served as Chairman & CEO of Synvista Therapeutics, Inc. He was also President & CEO of Mylan Bertek Pharmaceuticals, Inc. and Senior Vice President of Mylan Laboratories, Inc. Mauzey was the CEO of Innovex Worldwide and Director of OraPharma, Inc. Additionally, he served as an Independent Director of POZEN, Inc. Mauzey holds an undergraduate degree from Lewis University and an MBA from Xavier University.
Eerdere bekende functies van James Joseph Mauzey
Bedrijven | Functie | Einde |
---|---|---|
POZEN INC. | Directeur/Bestuurslid | 07-06-2012 |
Mylan Bertek Pharmaceuticals, Inc.
Mylan Bertek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Viatris, Inc., Mylan Bertek Pharmaceuticals, Inc. is a pharmaceutical company based in Research Triangle Park, NC. The company's focus is not mentioned in the provided metadata, as the description appears to be unrelated and potentially incorrect. | President | 01-07-2004 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA. | Corporate Officer/Principal | 30-06-2004 |
OraPharma, Inc.
OraPharma, Inc. Pharmaceuticals: MajorHealth Technology OraPharma, Inc. develops and produces drugs for oral diseases. It offers a suite of products to address a range of patient concerns from the foundation of gums, bone, and teeth to the aesthetics of a whiter smile. The company's products include ARESTIN Microspheres, a locally administered antibiotic indicated as an adjunct to scaling and root planning procedures for the reduction of pocket depth in patients with adult periodontitis; and ONSET Approach, a unique delivery system of locally buffered anesthesia that provides faster onset of anesthesia and a comfortable injection. The company was founded in 1996 and is headquartered in Horsham, PA. | Directeur/Bestuurslid | 01-01-2003 |
Innovex Worldwide | President | 01-01-2000 |
Opleiding van James Joseph Mauzey
Xavier University | Masters Business Admin |
Lewis University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
SYNVISTA THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA. | Health Technology |
OraPharma, Inc.
OraPharma, Inc. Pharmaceuticals: MajorHealth Technology OraPharma, Inc. develops and produces drugs for oral diseases. It offers a suite of products to address a range of patient concerns from the foundation of gums, bone, and teeth to the aesthetics of a whiter smile. The company's products include ARESTIN Microspheres, a locally administered antibiotic indicated as an adjunct to scaling and root planning procedures for the reduction of pocket depth in patients with adult periodontitis; and ONSET Approach, a unique delivery system of locally buffered anesthesia that provides faster onset of anesthesia and a comfortable injection. The company was founded in 1996 and is headquartered in Horsham, PA. | Health Technology |
POZEN, Inc.
POZEN, Inc. Pharmaceuticals: MajorHealth Technology POZEN, Inc. manufactures and markets pharmaceutical products. Its Pipeline products are PA Product Portfolio, which is focused on integrated aspirin therapies that enable the full power of aspirin by reducing its potential gastrointestinal damage. The firm PA Product Portfolio consists of PA8140 and PA32540. The company was founded by John R. Plachetka in 1996 and is headquartered in Raleigh, NC. | Health Technology |
Mylan Bertek Pharmaceuticals, Inc.
Mylan Bertek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Viatris, Inc., Mylan Bertek Pharmaceuticals, Inc. is a pharmaceutical company based in Research Triangle Park, NC. The company's focus is not mentioned in the provided metadata, as the description appears to be unrelated and potentially incorrect. | Health Technology |
Innovex Worldwide |